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Abstract  
Objectives Individual activities of N-acetyltransferase 2, NAT2, and of xanthine oxidase, XO, can be 
assessed using ratios of urinary caffeine metabolites. We investigated how ratios changed over time 
and which urine collection interval would be the best for NAT2 and XO activity assessments.  
Methods On two occasions separated by 14 days, sixteen healthy male Caucasians collected urine 
before and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, and 16-24 h after 150 mg caffeine given in the framework 
of a phenotyping cocktail study. The metabolites 5-acetylamino-6-formylamino-3-methyluracil 
(AFMU), 5-acetylamino-6-amino-3-methyluracil (AAMU), 1-methylxanthine (1X) and 1-methylurate 
(1U) were quantified with LC-MS/MS. The molar ratio (AFMU+AAMU)/(1X+1U+AFMU+AAMU) 
was used as NAT2 metric, while the ratio 1U/(1X+1U) served as XO metric.  
Results The NAT2 ratios were stable in the intervals 4-24 h after caffeine dosing. Mean intraindividual 
coefficients of variation were 11-23% starting 4 hours postdose, while interindividual variability 
reached 37-75%. The XO ratios increased gradually by 14% from the 2-4 to the 16-24 h interval. The 
mean intra- and interindividual coefficients of variation of XO activity were 3-18%, and 7-10%, 
respectively. No significant differences between study occasions were observed.  
Conclusions Any sampling interval at least 4 hours after caffeine dosing is suitable for NAT2 and XO 
activity assessments. XO activities can only be compared between volunteers and studies, if the same 
urine collection schedule has been respected. The low intraindividual variabilities allow for sample 
sizes of 16 and 6 participants in crossover interaction studies of NAT2 and XO activity, respectively.  
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Introduction  
The genetically polymorphic phase-II enzyme N-acetyltransferase type 2 (NAT2) is important for the 
metabolism of drugs like isoniazid and several sulfonamides, and is involved in the bioactivation of 
several procarcinogens, e.g. from tobacco smoke [1]. More than 50 allelic variants have been 
described, and approximately 50% of Caucasians are classified as slow acetylators.  
 
The enzyme xanthine oxidase (XO) plays a crucial role in many metabolic processes: it produces 
reactive oxygen species, catalyses uric acid production and plays a role in the elimination of thiopurine 
drugs [2-4]. About 20 genetic variants are known [5], but in studies, 4% or less of volunteers 
examined showed a decreased enzyme activity [6]. However, xanthine oxidase activity is also 
influenced by endogenous compounds, other drugs (e.g. inhibition by the allopurinol metabolite 
oxypurinol or induction by cytokines or ethacrynic acid) and environmental factors [2, 3].  
 
Since the 1980’s, the quantification of urinary caffeine metabolites was used frequently to assess the 
actual activities of NAT2 [7, 8] and XO [9]. A variety of different metabolite ratios, sampling schemes 
and schedules have been developed and are used in different study settings. Not every approach has 
been fully validated, so that the results may not always be reliable and comparable. Generally, NAT2 
activity assessment attracted more attention than XO activity estimation. It is hence important to know 
whether differences between the phenotyping procedures relevantly affect the results and deteriorate 
their comparability. In this context, we have shown earlier that caffeine from uncontrolled dietary 
sources may be used for NAT2 phenotyping, if a correct abstinence period is respected [10]. The 
present work was carried out to investigate whether the timing of urine collections, which differs 
considerably between publications, has a relevant influence on NAT2 and XO phenotype assessments, 
and whether both intra- and interindividual variability change as a function of (urine collection) time. 
Since intraindividual variability is a crucial factor for the correct estimation of sample sizes in 
crossover interaction studies, we determined the numbers of participants necessary for the reliable 
estimation of changes in NAT2 and XO activities in such a study setting.  
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Methods  
Study conduct and subjects  
This investigation is based on urine samples collected in the framework of a two-period, randomised 
crossover interaction study in 16 healthy, young, non-smoking male Caucasians which was carried out 
to assess the effect of propiverine on the activities of hepatic CYP3A (using intravenous midazolam), 
intestinal CYP3A (oral midazolam), CYP2C9 (tolbutamide), CYP2C19 (mephenytoin), and CYP1A2 
(150 mg caffeine, Percoffedrinol tablets, Passauer, Berlin, Germany) and which has been published 
earlier [11]. All volunteers gave their written informed consent before the screening examination. The 
study was endorsed by the Ethics Committee of the University of Cologne, Germany, and conducted 
according to the principles of Good Clinical Practice and the laws of Germany. The cocktail was given 
under controlled in-house conditions on day 7 of regular administration of 15 mg propiverine or 
placebo twice daily. A washout period of 14 days was respected between the 2 cocktail 
administrations. Any methylxanthine containing food or beverage was forbidden from 72 h before the 
first drug intake until 48 h after the last dosing. Besides blood collections for the main purposes of the 
study, urine was collected before, and at 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, and 16-24 h after caffeine 
intake. The urine containers were kept at +4C° during the collection periods, and the participants were 
instructed to void all urine during the collection periods in the containers. Weight and pH of the urine 
collection were recorded, and acidified samples (1mL 6M HCl) were stored at -20°C until analysis.  
 
Quantification of caffeine metabolites in urine  
The caffeine metabolites 5-acetylamino-6-formylamino-3-methyluracil (AFMU), 5-acetylamino-6-
amino-3-methyluracil (AAMU), 1-methylxanthine (1X) and 1-methylurate (1U) were quantified with 
a fully validated LC-MS/MS method as described earlier without modification [10]. The lower limit of 
quantification was 100 ng/mL for all analytes except for AAMU, where it was 200 ng/mL.  
 
Statistical analysis  
For each sampling interval, the molar urinary ratios (AFMU+AAMU)/(AFMU+AAMU+1X+1U) 
were calculated as parameters of NAT2 activity [12]. As parameters of XO activity, the molar urinary 
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ratios (1U)/(1X+1U) were calculated [13]. To obtain estimates of intraindividual and interindividual 
variability, linear mixed models were established using maximum likelihood estimation based on ln-
transformed ratios of each collection period which took “sequence”, “period”, “comedication” as fixed 
effects, and “volunteer (sequence)” as random effect into account. The coefficient of variation of the 
multiplicative model from the residual variance was considered as the intraindividual variability, while 
the multiplicative coefficient of variation obtained from the covariance of the random effect “volunteer 
(sequence)” served as estimate of the interindividual variability. For the comparisons between 
sampling intervals, linear mixed effect models were fitted to assess the influence of collection time on 
the variability between collection periods. In these models, timing of collection intervals was handled 
as a continuous variable and included as an additional fixed effect. Statistical significance was 
accepted for p ≤ 0.05. The intraindividual CVs were used to estimate the sample size needed for a 
crossover interaction study with the NAT2 and XO metrics under the assumptions that the ratio μtest / 
μreference is in the 0.95 – 1.05 interval with 90% confidence intervals between 0.80 and 1.25, a power of 
0.80 and p = 0.05 [14]. SPSS 15.0.0 for windows (SPSS Inc., Chigago, IL, USA), Excel 2003 
(Microsoft Corp., Redmond, WA, USA), and SigmaPlot 10.0 (Systat Software Inc., San Jose, CA, 
USA) were used for statistical and graphical analysis.  
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Results  
N-acetyltransferase 2  
The urinary metabolite ratios which were used to assess the NAT2 activity were bimodally distributed 
starting with the 4-6 h collection period until the 16-24 h collection period (fig. 1). In the ANOVA 
based mixed effect modelling using ln-transformed metabolic ratios of these collection intervals, 
neither the timing of the urine collection (p = 0.60) nor the period (p = 0.28) or sequence (p = 0.38) 
were significant factors of influence, while comedication weakly influenced the overall model (p = 
0.04). The overall intraindividual variability was 19.9%, while interindividual variability reached 
67.0%. The modelling of the individual collection periods from 4 to 24 h postdose yielded 
intraindividual coefficients of variation of the metabolic ratios between 10.5 % (collection interval 16 - 
24 h postdose) and 23.3 % (collection interval 8 - 12 h postdose), while interindividual CVs ranged 
between 36.5 % and 74.8 % (table). No statistically significant influence of comedication, period, or 
sequence on the NAT2 ratios was observed in any model of the individual collection periods. Rapid 
and slow acetylators were well distinguished (fig. 1, fig. 2). Their respective overall means in 
metabolic ratios in urine collected between 4 and 24 h after 150 mg caffeine were 0.269 (CV, 18.7%) 
for rapid and 0.079 (CV, 31.9%) for slow acetylators. The acetylation phenotype did not change 
between the periods (fig. 2). It has to be noted, however, that in three cases, ratios in isolated sampling 
intervals were outside the range of their individual values and their group means. Urine samples 
collected before the caffeine test dose of 2 and 5 volunteers during period 1 and 2, respectively, 
contained concentrations of AFMU and / or AAMU which were above the quantification limit. Since 
the intraindividual CV was 17.5% during the 4-6 h collection interval, a sample sizes of n = 16 
volunteers appeared appropriate for crossover interaction studies using this parameter (alpha = 0.05, 
power 80 %, true µtest/µreference in the 0.95-1.05 range, “no effect” boundaries 0.8-1.25).  
 
Xanthine oxidase  
The ratios representing XO activity were unimodally distributed. In the overall linear mixed effect 
model, time was a significant factor of influence (p<0.00001) which lead to an increase in ratios by 
14.5% from the 2-4 h collection interval to the 16-24 h collection interval (fig. 3). While sequence (p = 
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0.90) and comedication (p = 0.36) did not influence the ratios in the model, XO ratios during period 1 
were 3.1% higher than during period 2 (p = 0.024). In this model, the interindividual variability 
reached 8.2%, while the global intraindividual coefficient of variation was 9.2%. The arithmetic 
means, inter- and intraindividual coefficients of variation for the individual collection periods are 
shown in the table. The lowest intraindividual coefficient of variation was 2.6%, observed in the 
collection interval 2-4 h postdose, while the highest was 18.2%, observed in the collection interval 6-8 
h after caffeine intake. The mean interindividual coefficients of variation ranged between 6.5% and 
10.3% (table). In the individual models for each collection period, no statistically significant 
influences of the factors study period (fig. 4), sequence, or comedication were observed. Before 
dosing, the concentrations of 1 U were above the quantification limit in the urine of all volunteers, and 
concentrations of 1 X were quantifiable in 13 and 14 urine samples before the first and the second 
caffeine intake, respectively. Taking the same sampling interval and the same conditions for sample 
size estimation as used for NAT2 into account, the intraindividual variability of XO activity in the 4-6 
h collection interval of 3.6% would lead to a sample size of n = 6 for crossover interaction studies.  
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Discussion  
Although many investigations use urinary metabolite ratios for the assessment of NAT2 and XO 
activities, to our knowledge, the question of the appropriate urine sampling interval, which is of 
importance for the validity and comparability of results, has not yet been scrutinised. In the present 
investigation, a short urine sampling interval of two hours duration was sufficient if more than 4 or 2 
hours after the caffeine test dose had elapsed, respectively. While for NAT2 phenotyping, the exact 
choice of collection time then had no relevant influence on the adequacy of the results, XO activity 
parameters increased gradually with time. These results may facilitate future research in this area and 
may help to appreciate the formal correctness of earlier results.  
For NAT2 phenotyping, three ratios based on urinary caffeine metabolites have been proposed [15]. 
The ratio used in the present investigation is an extension of the ratio proposed by Tang and co-
workers [12] which has been most frequently used and fairly well validated [10 and references 
therein]. Since both AFMU and AAMU are included in the formula we used, questions and problems 
surrounding the deformylation of AFMU [10, 16] were avoided.  
For the assessment of XO activity, the ratios 1U/1X and (1U)/(1X+1U) have been used and validated 
in combination with NAT2 and CYP1A2 assessments [17-21] and in the framework of cocktail 
phenotyping studies [22-24]. No direct comparison between the performance of the two ratios has 
been published and for both, some validation issues have not yet been addressed. However, the latter 
ratio is more easily interpreted (the more 1U is formed and the more active XO is, the closer the values 
are to 1), and it can still be calculated if all 1X has been converted to 1U. Since 1X appears to be also a 
substrate for renal organic anion transporters, inhibition of these transporters, e.g. by probenecid, has 
an influence on the ratio [21, 25, 26].  
Traditionally, most studies investigating NAT2 and XO activities use 6 hours, 8 hours, or 12 hours 
urine sampling intervals or spot urine samples between 4 and 8 hours after intake of the caffeine test 
dose. While the latter may have advantages in large scale studies where urine collections over longer 
periods may be impractical, our data suggest that, if a urine collection is carried out, it is sufficient to 
collect for 2 hours at least 4 hours after the dosing. For NAT2 phenotyping, the collection interval 4 to 
6 hours after caffeine intake may be the best compromise between accuracy of results (fig. 1 and 2, 
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table) and practicability for participants and investigators (duration of caffeine abstinence and urine 
collection). Longer collection periods may bear the risk that the caffeine abstinence is not observed. 
Interestingly, early publications on NAT2 phenotyping denied the need for caffeine abstinence [8, 27].  
In the present investigation, we observed intraindividual variabilities in NAT2 ratios between 10.5% 
and 23.3% from 4 h after dosing, and in XO ratios between 2.6% and 18.2% from 2 h after dosing. 
Only few published studies quantify the intraindividual variability of NAT2 or XO. The 
intraindividual variability is reported to be in a range between 6% and 49% for NAT2 [8, 27], and 
about 5% for XO [18]. We could substantiate that the intraindividual variability for both NAT2 and 
XO activity is low, at least under the controlled conditions of a randomised clinical study. This allows 
e.g. the conduct of crossover interaction studies with low numbers of participants. However, in three 
urine collections 6 or more hours after caffeine dosing, NAT2 ratios were outside the range of the 
other individual values and in the range of the opposite acetylator phenotype. For XO, data in two 
volunteers, one in each period and direction, deviated markedly from the mean starting with the 6-8 h 
collection interval. These deviations had an impact on the estimations of the intraindividual 
variabilities in the respective collection periods. Since the first food intake took place 6 h after caffeine 
dosing, it may be speculated whether food intake had an influence, however, food was standardised, 
and it remains elusive why outlying values were only observed in one volunteer in each period. The 
influences of comedication and period which were observed in the overall models for NAT2 and XO 
phenotyping, respectively, were not observed in single collection period models. Hence, these factors 
did not influence the estimations of the variabilities for the individual collections, and may have been 
observed by chance.  
In predose urine samples of most volunteers, some caffeine metabolites were quantified in 
low concentrations. It may be speculated that the low quantification limits of our analytical 
method enabled the quantification of these metabolites which may have resulted from low-
dose contamination of food and beverages with methylxanthines. Noncompliance seemed 
unlikely, since volunteers were under observation during the night before the phenotyping 
day, and they were regularly questioned about adherence to dietary restrictions.  
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Since for XO activity, both intra- and interindividual variability were lower than for NAT2 activity, 
and since samples from 2-24 h after caffeine intake may be used for XO activity assessment, the best 
choice for XO phenotyping will be to use the same 4-6 hours collection interval as used for NAT2 
phenotyping (fig. 4).  
In conclusion, the present investigation scrutinised the influence of timing of urine collection intervals 
on the NAT2 and XO activity parameters. Although the use of a urine collection 4 to 6 h after caffeine 
dosing appears to be the optimum, most other later collection schedules yield valid results, if at least 4 
hours (2 hours for XO phenotyping) have elapsed. It has to be noted that timing of the collection 
interval influences the results of XO phenotyping. Hence, XO activities quantified at different time 
intervals are not comparable. In consideration of the low intraindividual coefficients of variation, 
crossover studies which investigate the interaction of a drug with NAT2 or XO using the same ratios 
as used here may be carried out with a number of participants as low as 16 and 6, respectively.  
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Legends to table and figures  
 
Table: arithmetic means, interindividual (CVinter) and intraindividual coefficients of variation (CVintra) 
for the urinary molar ratios for NAT2 and XO activity. 
 
Figure 1: individual NAT2 metabolic ratio - time courses in 16 healthy non-smokers in the first (upper 
part) and second (lower part) period of a crossover study. Time values are in the middle of collection 
intervals.  
 
Figure 2: Comparison of individual NAT2 activities quantified in urine collected 4 – 6 h after dosing 
between the two periods.  
 
Figure 3: individual XO metabolic ratio - time courses in 16 healthy non-smokers in the first (upper 
part) and second (lower part) period of a crossover study. Time values are in the middle of collection 
intervals.  
 
Figure 4: Comparison of individual XO activities quantified in urine collected 4 – 6 h after dosing 
between the two periods.  
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Table: arithmetic means, interindividual (CVinter) and intraindividual coefficients of variation (CVintra) for the urinary molar ratios for NAT2 and XO activity.  
 NAT2 (all 16 participants) NAT2 rapid acetylators (n=7) NAT2 slow acetylators (n=9) Xanthine oxidase (n=16) 
Sampling interval Mean  CVinter CVintra Mean  CVinter CVintra Mean  CVinter CVintra Mean  CVinter CVintra 
Period 1: predose n.c. n.c. n.c. 0.820 
Period 2: predose n.c. 
n.c. n.c.  
n.c. 
n.c. n.c. 
n.c. 
n.c. n.c. 
0.812 
3.6% 9.4% 
Period 1: 0-2 h 0.112 0.148 0.077 0.520 
Period 2: 0-2 h 0.119 
49.1% 27.6% 
0.165 
9.1% 14.6% 
0.065 
29.1% 27.4% 
0.534 
7.9% 5.5% 
Period 1: 2-4 h 0.134 0.235 0.059 0.541 
Period 2: 2-4 h 0.150 
82.2% 15.0% 
0.277 
5.0% 6.8% 
0.065 
20.5% 14.3% 
0.549 
6.5% 2.6% 
Period 1: 4-6 h 0.161 0.267 0.078 0.556 
Period 2: 4-6 h 0.163 
74.8% 17.5% 
0.279 
7.4% 10.2% 
0.074 
24.1% 19.5% 
0.571 
6.9% 3.6% 
Period 1: 6-8 h 0.152 a 0.245 a 0.071 0.600 a 
Period 2: 6-8 h 0.180 
68.3% 20.0% 
0.290 
10.6% 24.7% 
0.084 
18.3% 11.8% 
0.556 a 
10.3% 18.2% 
Period 1: 8-12 h 0.167 0.267 0.089 0.604 
Period 2: 8-12 h 0.186 a 
36.5% 23.3% 
0.299 
2.2% 15.3% 
0.098 a 
14.1% 26.7% 
0.580 
8.7% 6.4% 
Period 1: 12-16 h 0.169 0.274 0.087 0.611 
Period 2: 12-16 h 0.166 a 
36.6% 16.8% 
0.262 a 
22.5% 20.2% 
0.082 
19.6% 7.9% 
0.583 
7.4% 8.5% 
Period 1: 16-24 h 0.160 0.257 0.076 0.642 
Period 2: 16-24 h 0.165 
66.6% 10.5% 
0.274 
9.5% 13.2% 
0.081 
15.5% 5.5% 
0.624 
7.8% 4.6% 
n.c., not calculated since analytes were below the quantification limit in more than 50% of participants; a, including one outlier, see text for details  
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Figure 1: individual NAT2 metabolic ratio - time courses in 16 healthy non-smokers in the first (upper 
part) and second (lower part) period of a crossover study. Time values are in the middle of collection 
intervals.  
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Figure 2: Comparison of individual NAT2 activities quantified in urine collected 4 – 6 h after dosing 
between the two periods.  
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Figure 3: individual XO metabolic ratio - time courses in 16 healthy non-smokers in the first (upper 
part) and second (lower part) period of a crossover study. Time values are in the middle of collection 
intervals.  
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Figure 4: Comparison of individual XO activities quantified in urine collected 4 – 6 h after dosing 
between the two periods.  
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